ATLANTA, Nov. 13, 2012 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology treatment and research, today announced findings from studies that evaluated the long-term outcomes, dosing, safety and impact on daily living of Cimzia ® (certolizumab pegol) for adults with moderate to severe rheumatoid arthritis (RA). The data were presented at the American College of Rheumatology's (ACR) 2012 Annual Scientific Meeting in Washington, D.C., November 10-14, 2012. "Because RA is a chronic disease that requires ongoing management, it is important to evaluate anti-TNF therapy in the long-term clinical setting. Studying this can help us to better understand long-term outcomes for patients who wish to maintain their health-related quality of life and ability to participate in daily activities," said Dr. Roy Fleischmann, Clinical Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center. In the U.S., Cimzia ® is indicated for the treatment of adult patients with moderately-to-severely active RA. In the European Union, Cimzia ® in combination with methotrexate (MTX) is indicated for the treatment of moderate-to-severe active RA in adult patients inadequately responsive to disease-modifying anti-rheumatic drugs (DMARDs) including MTX. Cimzia ® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. An Analysis of Two Maintenance Dosing Regimens: The DOSEFLEX Trial Presentation Title: Certolizumab Pegol Plus Methotrexate is Similarly Effective in Active Rheumatoid Arthritis Patients With or Without Secondary Non-Response to TNF Inhibitors: Post-hoc Analysis of a Phase IIIB Trial
Monday, November 12, 2012, from 9:00 AM - 6:00 PM
Location: Walter E. Washington Convention Center (WCC): Poster Hall (Hall B)
Results from the DOSEFLEX trial showed that in a population of adult patients with active moderate to severe RA, two dosing regimens of certolizumab pegol (200 mg every two weeks and 400 mg every four weeks*) plus methotrexate (MTX) showed comparable efficacy versus placebo and MTX in maintaining clinical response.